Cyclosporin A treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patients

Dermatitis. 2007 Sep;18(3):163-5. doi: 10.2310/6620.2007.06025.

Abstract

Cyclosporin A is increasingly used in the treatment of severe refractory atopic dermatitis. Although cyclosporin A treatment is highly efficacious and relatively safe, we report four adult atopic dermatitis (AD) patients who deteriorated during long-term cyclosporin A treatment, with clinical signs and symptoms more severe than at the onset of treatment. Interestingly, these patients showed large increases of total serum immunoglobulin E (IgE) levels, paralleled by increasing disease severity and serum levels of thymus and activation-regulated chemokine. This implies that cyclosporin A may induce a shift to Th2, resulting in increased IgE synthesis, in a subpopulation of AD patients. We therefore suggest that in this subpopulation, treatment with anti-B cell or combined anti-B and T-cell treatment may be favorable.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cyclosporine / administration & dosage
  • Cyclosporine / adverse effects*
  • Dermatitis, Atopic / blood
  • Dermatitis, Atopic / drug therapy*
  • Dermatitis, Atopic / immunology
  • Dermatitis, Atopic / pathology
  • Diagnosis, Differential
  • Eczema / chemically induced
  • Eczema / diagnosis*
  • Eczema / pathology
  • Humans
  • Immunoglobulin E / blood*
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*

Substances

  • Immunosuppressive Agents
  • Immunoglobulin E
  • Cyclosporine